Regenesome to Exhibit at IVS Startup Market, Japan's Largest Startup Conference "IVS2026" / July 2 (DAY2) at Kyoto Miyako Messe

Regenesome Co., Ltd. (Headquarters: Minato-ku, Tokyo; Representative Director: Zentaro Sakuma), a subsidiary of Space Seed Holdings Inc. (Headquarters: Minato-ku, Tokyo; Representative Director: Kengo Suzuki), announced its participation in the "IVS Startup Market," an exhibition and networking space at "IVS2026" (July 1-3, 2026, at Kyoto Miyako Messe and other venues), Japan's largest startup conference hosted by Headline Japan Inc.

Regenesome will exhibit on the second day, DAY2 (July 2, 2026), at booth number SA-33. This exhibition is considered one of the initiatives to promote the societal implementation of aging control and regenerative medicine using nanoparticles.

Exhibition Details

Item

Details

Event Name

IVS2026 / IVS Startup Market

Dates

July 1 (Wed) - July 3 (Fri), 2026

Exhibiting Company

Regenesome Co., Ltd.

Exhibition Date

July 2, 2026 (DAY2)

Booth Number

SA-33

Venue

Kyoto Miyako Messe and other venues (Sakyo-ku, Kyoto City)

Organizer

Headline Japan Inc.

"IVS Startup Market" is an exhibition and networking space where leading domestic startups gather. Regenesome views this market, which brings together investors, corporations, research institutions, and potential partners, as a platform for dialogue to deliver nanoparticle technology and aging control research to society, and will introduce its business at booth SA-33 on DAY2.

Click here for IVS event information

What Regenesome Aims to Convey

Regenesome is a bio-venture company aiming to "solve challenges of aging with biotechnology" and strives to establish aging control and regenerative medicine using nanoparticles such as liposomes. The company's mission is to "provide anti-aging technology applicable to Earth, necessary for humanity to expand its living sphere to the moon in 2040," and its vision is to "demonstrate anti-aging technology that extends healthy life expectancy by 2030."

At this market, Regenesome plans to introduce its research and development directions and their application to longevity challenges on Earth, aiming to foster dialogue for co-creation.

Future Developments

Based on the dialogues held during the event, Regenesome plans to proceed with the following:

Promote dialogue with corporate venture capital, CVCs, and VCs in the longevity and regenerative medicine fields.

Discuss joint research and business collaborations for the societal implementation of aging control and regenerative medicine using nanoparticles.

Continue initiatives connecting longevity research on Earth with space healthcare.

Specific collaborations will be announced sequentially upon reaching agreements with the respective parties.

About Regenesome Co., Ltd.

Regenesome aims to provide new solutions for aging suppression and regenerative medicine utilizing nanoparticles. The company has established its headquarters and research facility, "Takanawa Longevity Lab," at TAKANAWA GATEWAY CITY's "LiSH (Link Scholars' Hub)" and is accelerating research and development for the expansion of its healthcare business under its own brand "SAISEI LAB" and for future entry into the medical field. In the future, the company aims to contribute to humanity's expansion into space along with the extension of healthy life expectancy. https://regenesome.com/

About Space Seed Holdings Inc.

Space Seed Holdings is a space-focused deep tech venture builder that engages in investment, research, and business creation with the mission to "make science fiction a non-fiction." Centered around programs such as the "Fermentation and Longevity Fund," which supports the societal implementation of fermentation and longevity technologies, the company is working to create businesses that solve societal issues. By 2040, it aims to provide the technologies necessary for humanity to inhabit space, in collaboration with various stakeholders. https://ss-hd.co.jp/